Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit ...

Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

For more on Prasad’s return, go here; for a “Matt’s Take” on Prasad, go here; for the latest on investors’ attitudes toward ...

TheStreet. Good morning. The market is open. Investors are digesting the release of key economic data this morning, namely the Producer Price Index (PPI) and Initial / Continuing Jobless Claims. Both ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.